DSIP (Delta Sleep-Inducing Peptide) Research Peptide

Yes. Every batch of DSIP (Delta Sleep-Inducing Peptide) is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

Yes. The Certificate of Analysis for the batch currently in stock can be viewed and downloaded directly on this page, before you place an order. Each certificate states the batch number, the measured purity, and the date of analysis, and can be verified independently with the issuing laboratory using the report number it carries.

It means DSIP (Delta Sleep-Inducing Peptide) is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. DSIP is legal to purchase in the United States for in vitro and non-clinical laboratory research. It carries no FDA approval or therapeutic indication for human use. DSIP is not a scheduled substance under the Controlled Substances Act. Sold strictly for qualified research use, not human or veterinary administration.

DSIP (Delta Sleep-Inducing Peptide) ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

It is mostly negative or weak. The most quoted positive study, in 14 patients with chronic insomnia, reported that the efficiency of night sleep and of daytime rest reached the levels of normal controls, but FDA's 2026 review found that it had no placebo arm despite being described as placebo-controlled, and read it instead as compared with an externally matched control group. The one chronic-insomnia trial with a parallel placebo group, in 16 patients, reported weak effects that it said could partly reflect a change in the placebo group and concluded the compound was unlikely to be of major benefit. A randomized, double-blind, placebo-controlled crossover in six patients by a different group concluded that the sleep improvement it measured was of little clinical significance. The DSIP research article reports these studies.

The name records what its discoverers were looking for in the 1970s, not a settled finding. The compound also carries the international nonproprietary name emideltide, which makes no such claim. Published controlled studies in patients with chronic insomnia are mostly negative or weak. The founding trial found no change in sleep onset latency or final waking time against placebo, and two independent trials reported effects that were not significant, or weak and possibly a placebo-group artifact. FDA's 2026 review found that the most quoted positive study had no placebo arm. The DSIP research article reports these studies.